Global Renal Cell Carcinoma Expected to Get Boosted by Opdivo Release

Published Date : Oct 17, 2016

ALBANY, NY, Oct 17, 2016: The latest report, titled “PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast And Market Analysis To 2023,” empowers users with updated information on the market in terms of its pharmaceutical implementations. One of the key points elaborated on within the report is the growing need for specific pharmaceutical products for RCC and the largely unmet needs among its patients. 

According to the report, the global renal cell carcinoma market holds a massive space of unmet needs. The development of drugs and the release of upcoming drugs is expected to close this gap, facilitating a robust growth rate for the market. A key drug release expected in the global renal cell carcinoma market is Opdivo in a second-line setting. The market is also predicted to grow through the release of first-line setting combinations of the PD-1 modulator. The report shows how the demand for Opdivo is expected to rise intensely over the coming years. It is expected to overtake mTOR inhibitors and tyrosine kinase inhibitors, thereby becoming the leading SoC in second-line setting. 

The report also deals with the development pipeline for the global renal cell carcinoma market and elaborates on the various therapies in it. Each therapy is directed towards a particular RCC setting and will have differing results. As stated in the report, there will be a partial fulfillment of RCC unmet needs through the release of approved immunotherapies in either monotherapy or in a combined effort with other agents. This will not, however, completely satisfy the global renal cell carcinoma market, as there will still remain a large volume of unmet needs post launching of these agents. 

For Sample Copy, click here: 

Current therapies are explored in the report as it discusses the impact that each treatment already has on RCC and its patients. One of the key current drivers of the global renal cell carcinoma market is the growing number of cases of RCC within the 8MM. 

One of the key factors restraining the global renal cell carcinoma market is the inevitable launch of a huge volume of generics based on the current tyrosine kinase inhibitors as it is the standard treatment for RCC. 

The scope of the report includes a general overview of the global renal cell carcinoma market, which is a description of the treatment guidelines, diagnostic tools, symptoms, pathophysiology, etiology, and epidemiology of RCC. Core topics discussed in detail within the report include the implications of clinical trial mapping for RCC, the current volume of unmet needs, a brief characterization of the market, and the market’s competitive landscape. 

The report will enable its users to gain a greater understanding of the global renal cell carcinoma market and allow them to perform functions such as designing and licensing their own in- and out-licensing methods, expand their existing business strategies, improve revenues by taking advantage of current market trends, and track the overall drug sales within the market within a forecast period from 2013 to 2023. 

To order report Call Toll Free: 866-997-4948 or send an email on